The impressive success of T-DXd has prompted the initiation of multiple clinical trials aimed at assessing its potential synergies with immune checkpoint inhibitors, endocrine therapy, and chemotherapy, among other therapeutic modalities, in the treatment of low HER2 breast cancer (NCT04556773). Here, ERBB2 is linked to breast cancer.